Walkthrough · public protocol

One real protocol, start to finish.

We wanted to show Loom on a protocol anyone can check. SWOG S1505 is public, it’s a real cancer trial, and it’s demanding: two chemotherapy regimens, surgery in between, and follow-up over years. Here is the study, what it found, and what Loom did with its protocol.

Study
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Registry
NCT02562716 on ClinicalTrials.gov
Sponsor
SWOG Cancer Research Network
Design
Phase 2, randomised, two arms; chemotherapy before and after surgery
Primary outcome
Overall survival
Status
Completed

The study

SWOG S1505 (NCT02562716)

S1505 was a randomised phase 2 trial run by the SWOG Cancer Research Network with the US National Cancer Institute. It asked whether giving chemotherapy both before and after surgery could help people with pancreatic adenocarcinoma that can be removed by surgery. Patients were randomised to one of two regimens, mFOLFIRINOX (fluorouracil, irinotecan and oxaliplatin) or gemcitabine with nab-paclitaxel, given for 12 weeks before surgery and 12 weeks after. The primary outcome was overall survival at two years.[1][2]

To take part, patients needed a confirmed tissue diagnosis, a tumour judged resectable on imaging, and a performance status of 0 or 1. Its outcome measures are timed from more than one starting point: registration, the last dose of the third preoperative cycle, and surgery.[1][2]

What it found

The published outcome.

147 patients enrolled at academic and community centres across the US, and 102 were eligible and evaluable. Two-year overall survival was 47% with mFOLFIRINOX and 48% with gemcitabine and nab-paclitaxel. Neither was significantly above the trial’s 40% threshold, so the trial did not show better survival than earlier trials of chemotherapy after surgery alone. It did show that chemotherapy around surgery was tolerable, with high rates of successful resection, and that strict resectability criteria were hard to apply: central radiology review found 43 of the enrolled patients (29%) had disease beyond them.[2]

Of the 77 eligible patients who went on to surgery, 73 had their tumour removed.[3]

[founder to approve the summary; a clinician’s read is advised before launch]

What Loom did

Read.

Loom read S1505’s protocol, [founder to confirm: the protocol document posted with the ClinicalTrials.gov record, and its version]. S1505 is one of the public protocols we hold out of Loom’s development: we test Loom on them and don’t tune it on them. [founder to confirm this still holds for the run the page shows]

Drafted.

From it, Loom drafted the study map: the objectives and endpoints, the eligibility criteria, and the visits and assessments, each item linked to the passage it came from.

Studies / S1505 / Map

Study map

Draft · from the protocol

Primary objectives
To assess 2-year overall survival in each treatment arm (fluorouracil, irinotecan hydrochloride, and oxaliplatin [modified (m)FOLFIRINOX] and gemcitabine/nab-paclitaxel) in patients with resectable pancreatic cancer.

Endpoint

Overall survivalPrimary · 2 years

Arms

Arm I · mFOLFIRINOXDays 1 and 15
Arm II · Gemcitabine/nab-paclitaxelDays 1, 8, 15
Public protocol · S1505 · Example

Forms.

[Placeholder. No eCRF run on S1505 is recorded yet. Once a run is recorded, write what Loom drafted, for example: “Once the map was approved, Loom drafted the forms and placed them at their visits, each question linked back to its passage.”]

Studies / S1505 / Forms
Screening

Before registration

Eligibility19 questions
Surgical consult3 questions
Preoperative · Cycles 1–3

Every 28 days

Preoperative treatment8 questions
Response assessment3 questions
Surgery

4–8 weeks after Cycle 3

Surgery1 needs review
Pathology4 questions
Common logs

Not tied to a visit

Adverse events7 questions
Public protocol · S1505 · Example

Flagged.

Where the protocol’s own words didn’t settle something, Loom didn’t guess: it raised a question for the team and set the passages beside it. We count those flags as Loom doing its job. A good flag is a decision a person would have had to make anyway, found early and shown with its evidence.

[Placeholder: S1505’s flags from the run the page shows, each with its section and page, and how the team settled it.]

Studies / S1505 / Map / Surgery

When does the 4–8 week window start?

Visit · Needs a decision

Detailed description · Outline
undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment
Outcome measures
within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy
Public protocol · S1505 · Example

After the evaluation report

How well Loom did.

We’ll publish Loom’s results on S1505 with the method behind them and the misses, once our held-out evaluation report is final. Until then, we’d rather show you the work than a number.

A question we keep asking

Every trial starts helping people only once its first participant enrols. How many more patients could be helped if every study reached that day sooner?

Sources

  1. ClinicalTrials.gov. A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma (S1505). NCT02562716. Sponsor: SWOG Cancer Research Network; collaborator: National Cancer Institute. clinicaltrials.gov/study/NCT02562716 (read 2026-11-10).
  2. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421-427. doi:10.1001/jamaoncol.2020.7328.
  3. Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481-486. doi:10.1097/SLA.0000000000004155.